- Home
- QLGN vs INM Comparison
QLGN vs INM Comparison
Compare QLGN & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- INM
- Stock Information
- Founded
- QLGN 1996
- INM 1981
- Country
- QLGN United States
- INM Canada
- Employees
- QLGN N/A
- INM N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- QLGN Health Care
- INM Health Care
- Exchange
- QLGN Nasdaq
- INM Nasdaq
- Market Cap
- QLGN 4.8M
- INM 4.3M
- IPO Year
- QLGN N/A
- INM N/A
- Fundamental
- Price
- QLGN $5.02
- INM $2.28
- Analyst Decision
- QLGN
- INM
- Analyst Count
- QLGN 0
- INM 0
- Target Price
- QLGN N/A
- INM N/A
- AVG Volume (30 Days)
- QLGN 4.8M
- INM 93.9K
- Earning Date
- QLGN 11-13-2025
- INM 11-13-2025
- Dividend Yield
- QLGN N/A
- INM N/A
- EPS Growth
- QLGN N/A
- INM N/A
- EPS
- QLGN N/A
- INM N/A
- Revenue
- QLGN N/A
- INM $4,942,633.00
- Revenue This Year
- QLGN N/A
- INM N/A
- Revenue Next Year
- QLGN N/A
- INM N/A
- P/E Ratio
- QLGN N/A
- INM N/A
- Revenue Growth
- QLGN N/A
- INM 7.50
- 52 Week Low
- QLGN $1.61
- INM $1.72
- 52 Week High
- QLGN $10.45
- INM $8.27
- Technical
- Relative Strength Index (RSI)
- QLGN 61.57
- INM 49.66
- Support Level
- QLGN $4.91
- INM $2.17
- Resistance Level
- QLGN $6.16
- INM $2.30
- Average True Range (ATR)
- QLGN 1.00
- INM 0.12
- MACD
- QLGN 0.06
- INM 0.01
- Stochastic Oscillator
- QLGN 43.01
- INM 41.16
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.